How do I buy Cogent Biosciences, Inc. Common Stock (COGT) stock?

Buying Cogent Biosciences, Inc. Common Stock (COGT) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "COGT", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy COGT by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for COGT on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Cogent Biosciences, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Cogent Biosciences, Inc. Common Stock (COGT) pay dividends?

At the moment, Cogent Biosciences, Inc. Common Stock (COGT) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track COGT's performance via the price chart in the Gotrade app.

Is buying COGT on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy COGT?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if COGT is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Cogent Biosciences, Inc. Common Stock (COGT) Stock Price: Nov 11 Close $29.40

Latest news

Zacks Investment Research

Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

COGTAugust 13, 2026

Zacks Investment Research

Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

COGT

Proactive Investors

Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts

COGTMarch 30, 2026

Proactive Investors

Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts

COGT

The Motley Fool

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

COGTMarch 21, 2026

The Motley Fool

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

About Cogent Biosciences, Inc. Common Stock

No description available.

SectorHealthcare

IndustryBiotechnology

Employees258

CEOMr. Andrew R. Robbins M.B.A.

IPO DateMar 29, 2018

HeadquartersWaltham, MA

Key Executives

Name	Title	Year Born
Mr. Andrew R. Robbins M.B.A.	President, CEO & Director	1976
Mr. John L. Green C.A., CPA	CFO & Principal Accounting Officer	1980
Dr. John Edward Robinson Ph.D.	Chief Scientific Officer	1974
Dr. Jessica Sachs M.D.	Chief Medical Officer	1975
Mr. Cole Pinnow	Chief Commercial Officer	1975
Mr. Brad Barnett	Chief Technology Officer	—
Ms. Christi Waarich	Senior Director of Investor Relations	—
Mr. Evan D. Kearns J.D.	Chief Legal Officer & Corporate Secretary	1980
Mr. Abb Hayden	Senior Vice President of Sales	—
Ms. Erin Schellhammer	Chief People Officer	—

Fundamentals

Valuation

Price-to-book value10.66

Profitability

Return on Equity-73.00%

Return on Assets-49.00%

EBITDA$-367.19M

Trading

Average volume2,160,420

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 43.38
MACD 12/26/9: -0.12
EMA 9 of MACD: -0.18
MACD histogram: 0.06
SMA 50: $31.63; Price below SMA 50
EMA 50: $32.07; Price below EMA 50
SMA 200: $35.39; Price below SMA 200
EMA 200: $34.79; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

3 analyst ratings

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Buy

100% Buy

0% Hold

0% Sell

Analyst price target

Low: $55.00
Average: $55.33
High: $56.00

Wedbush

David Nierengarten

Buy

Target price

$55.00

Piper Sandler

Christopher Raymond

Buy

Target price

$55.00

HC Wainwright & Co.

Robert Burns

Buy

Target price

$56.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-23.3	+14.2
2022	-13.1	-22.1	+22.0	-18.9	-33.1	+111.7	+18.1	+59.9	-12.2	-4.7	-1.9	-8.3
2023	+36.0	-12.8	-17.1	+0.1	+4.6	-6.9	+8.6	-8.5	-24.9	-14.6	-6.3	-26.2
2024	-29.0	+56.2	-7.1	-5.8	+15.6	+0.6	+5.5	+14.7	-1.4	+6.9	-18.9	-17.6
2025	+19.4	-16.2	-14.4	-10.0	-3.4	+28.0	+58.2	+6.0	+19.7	+15.4	+159.5	-10.7
2026	+3.4	+2.3	-1.0	+1.6	-4.6	+11.2	+1.2	-9.9	-7.7	-1.8	-1.1

Compare stocks

COGT

Buy COGT

Market cap

$5.12B

-

Price / Earnings ratio

-13.50

-

Price / Sales ratio

-

Dividend yield

0.00%

-

Average volume

2,160,420

-

Earnings per share

$-2.25

-

Cogent Biosciences, Inc. Common Stock (COGT) Stock

Key stats

Compare with COGT

Recent news

Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts

Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts

Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM

COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM

Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned

Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough

Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M

Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M

About Cogent Biosciences, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade